Krystal Biotech, Inc.

NasdaqGS:KRYS Stock Report

Market Cap: US$4.5b

Krystal Biotech Valuation

Is KRYS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KRYS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$696.03
Fair Value
77.6% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: KRYS ($156.07) is trading below our estimate of fair value ($696.03)

Significantly Below Fair Value: KRYS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KRYS?

Key metric: As KRYS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for KRYS. This is calculated by dividing KRYS's market cap by their current earnings.
What is KRYS's PE Ratio?
PE Ratio85.7x
EarningsUS$52.37m
Market CapUS$4.50b

Price to Earnings Ratio vs Peers

How does KRYS's PE Ratio compare to its peers?

The above table shows the PE ratio for KRYS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average20.3x
PTGX Protagonist Therapeutics
13.6x0.9%US$2.3b
ADMA ADMA Biologics
55.9x26.7%US$3.9b
AGIO Agios Pharmaceuticals
2.9x-29.8%US$1.9b
TRDA Entrada Therapeutics
8.6x-58.7%US$469.5m
KRYS Krystal Biotech
85.7x36.7%US$4.5b

Price-To-Earnings vs Peers: KRYS is expensive based on its Price-To-Earnings Ratio (85.7x) compared to the peer average (20.3x).

Price to Earnings Ratio vs Industry

How does KRYS's PE Ratio compare vs other companies in the US Biotechs Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROIV Roivant Sciences
1.8x-56.1%US$8.10b
AGIO Agios Pharmaceuticals
2.9x-29.8%US$1.92b
INBX Inhibrx Biosciences
0.1x-135.7%US$178.20m
CTMX CytomX Therapeutics
5x-13.8%US$64.17m
KRYS 85.7xIndustry Avg. 17.4xNo. of Companies10PE020406080100+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: KRYS is expensive based on its Price-To-Earnings Ratio (85.7x) compared to the US Biotechs industry average (17.4x).

Price to Earnings Ratio vs Fair Ratio

What is KRYS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KRYS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio85.7x
Fair PE Ratio36.2x

Price-To-Earnings vs Fair Ratio: KRYS is expensive based on its Price-To-Earnings Ratio (85.7x) compared to the estimated Fair Price-To-Earnings Ratio (36.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KRYS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$156.07
US$206.25
+32.2%
3.9%US$221.00US$195.00n/a8
Jan ’26US$156.66
US$207.78
+32.6%
4.2%US$221.00US$195.00n/a9
Dec ’25US$197.42
US$207.78
+5.2%
4.2%US$221.00US$195.00n/a9
Nov ’25US$176.39
US$207.22
+17.5%
4.0%US$221.00US$193.00n/a9
Oct ’25US$181.47
US$207.22
+14.2%
4.0%US$221.00US$193.00n/a9
Sep ’25US$195.12
US$205.44
+5.3%
3.4%US$221.00US$193.00n/a9
Aug ’25US$198.78
US$190.00
-4.4%
8.8%US$208.00US$153.00n/a9
Jul ’25US$182.27
US$189.00
+3.7%
8.5%US$208.00US$153.00n/a10
Jun ’25US$160.05
US$189.00
+18.1%
8.5%US$208.00US$153.00n/a10
May ’25US$159.67
US$188.50
+18.1%
9.2%US$208.00US$153.00n/a10
Apr ’25US$176.07
US$185.90
+5.6%
9.0%US$208.00US$153.00n/a10
Mar ’25US$167.82
US$182.70
+8.9%
9.2%US$208.00US$153.00n/a10
Feb ’25US$111.56
US$154.00
+38.0%
9.2%US$180.00US$130.00n/a10
Jan ’25US$124.06
US$154.00
+24.1%
9.2%US$180.00US$130.00US$156.6610
Dec ’24US$106.26
US$152.18
+43.2%
7.2%US$168.00US$130.00US$197.4211
Nov ’24US$119.31
US$151.40
+26.9%
7.4%US$168.00US$130.00US$176.3910
Oct ’24US$116.00
US$149.25
+28.7%
7.7%US$168.00US$130.00US$181.478
Sep ’24US$126.25
US$148.57
+17.7%
8.2%US$168.00US$130.00US$195.127
Aug ’24US$130.22
US$137.43
+5.5%
12.7%US$160.00US$100.00US$198.787
Jul ’24US$117.40
US$137.43
+17.1%
12.7%US$160.00US$100.00US$182.277
Jun ’24US$116.84
US$135.88
+16.3%
11.6%US$155.00US$100.00US$160.058
May ’24US$86.19
US$111.88
+29.8%
10.2%US$133.00US$100.00US$159.678
Apr ’24US$80.06
US$114.13
+42.5%
9.7%US$133.00US$100.00US$176.078
Mar ’24US$83.00
US$114.13
+37.5%
9.7%US$133.00US$100.00US$167.828
Feb ’24US$81.71
US$107.25
+31.3%
14.8%US$133.00US$79.00US$111.568
Jan ’24US$79.22
US$106.00
+33.8%
14.3%US$133.00US$79.00US$124.068
Analyst Price Target
Consensus Narrative from 8 Analysts
US$206.25
Fair Value
24.3% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 02:58
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Krystal Biotech, Inc. is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Alec StranahanBofA Global Research
Justin ZelinB. Riley Securities, Inc.